Fig. 3From: Circulating tumor cells criteria (CyCAR) versus standard RECIST criteria for treatment response assessment in metastatic colorectal cancer patientsEvaluation of FOLFOX–bevacizumab response by RECIST and CyCAR criteria together with CTCs VEGFR status. FR favorable response, NFR non-favorable response, w weekBack to article page